Mediastinal lymph node dissection has been adopted as standard treatment for adenocarcinoma of esophagogastric junction(AEJ). This multi-center, exploratory, prospective, cohort study aims at provide standard technical details of laparoscopic mediastinal lymph node dissection, and explore the potential clinical effects, gather key information for following study regarding sample size calculation, primary outcome and feasibility.
Introduction: Lower mediastinal lymph node dissection has been adopted as standard by treatment guideline for adenocarcinoma of esophagogastric junction(AEJ), but the effect of laparoscopic mediastinal lymph node dissection remains unknown. The aim of this study is to provide standard technical details of laparoscopic mediastinal lymph node dissection, and explore the potential clinical effects, gather key information for following study regarding sample size calculation, primary outcome and feasibility. This study report intervention development, governance procedures and selection and reporting of outcomes to optimize methods for using the Idea, Development, Exploration, Assessment, Long-term follow-up (IDEAL) framework for surgical innovation that informs evidence-based practice. Methods and analysis: This is an IDEAL stage II, prospective, parallel control, open label, multi-center and exploratory study. The inclusion criteria is Siewert II/ III, AEJ, cT2-4aN0-3M0(AJCC-8th Gastric Cancer TNM stage manual), decide to receive radical gastrectomy, without preoperative anti-neoplastic therapy. The individual included in the study is performed the radical total or proximal gastrectomy plus the lower mediastinal lymphadenectomy via either laparoscopic (trial arm) or open (control arm) TH approach. The surgical approach is determined by the investigator in each center before the operation and recorded in the electronic case report forms (CRF). The primary outcome is the number of lower mediastinal lymph nodes retrieved. Secondary outcome include complication, surgery length, postoperative death, R0 resection rate, etc. Expected sample size is 518 in each group, thus has 80% power to detect a difference of 0.17 in the average number of lower mediastinal lymph node dissected in between two groups.
Study Type
OBSERVATIONAL
Enrollment
1,036
Radical gastrectomy for gastric cancer should be consistent with Japanese gastric cancer treatment guideline.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
RECRUITINGThe number of lower mediastinal lymph nodes retrieved
The number of lower mediastinal lymph nodes retrieved
Time frame: immediately after the pathology report issued
Rate of complication during Lower Mediastinal Lymphadenectomy
Complication during Lower Mediastinal Lymphadenectomy \& anastomosis, including damage of pericardium, esophagus, etc.
Time frame: immediately after the surgery
Rate of postoperative complication after Lower Mediastinal Lymphadenectomy
Postoperative complication after Lower Mediastinal Lymphadenectomy, including leakage, bleeding, etc, complication related with Lower Mediastinal Lymphadenectomy
Time frame: Day 30 after surgery
Time length of Lower Mediastinal Lymphadenectomy
Time length of Lower Mediastinal Lymphadenectomy
Time frame: immediately after the surgery
Rate of Postoperative complication
Any complication within 30d after surgery
Time frame: Day 30 after surgery
Rate of postoperative death
death within 30 days after surgery
Time frame: Day 30 after surgery
Rate of unscheduled reoperation
reoperation within 30 days after surgery
Time frame: Day 30 after surgery
Rate of unscheduled readmission
unscheduled readmission within 30 days after surgery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Day 30 after surgery
R0 resection rate
R0 resection rate
Time frame: immediately after the pathology report issued
Proximal margin length
from proximal tumor margin to proximal margin
Time frame: 30minutes after removal of tumor
Local recurrence of lower mediastinal area in 3 years
Local recurrence of lower mediastinal area in 3 years
Time frame: Year 3 after surgery
Rate of cancer specific death in 3 years
Rate of cancer specific death in 3 years
Time frame: Year 3 after surgery
Recurrence free survival in 3 years
Recurrence free survival in 3 years
Time frame: Year 3 after surgery
Overall survival in 3 years
Overall survival in 3 years
Time frame: Year 3 after surgery